昊海生物科技股份有限公司（06826）于2025年11月27日发布翌日披露报表，披露当天在香港联交所回购78,900股H股。最高回购价为每股27.98港元，最低回购价为每股27.64港元，合计支付约2,199,366港元。本次回购股份尚未注销，约占公司现有已发行H股的0.0345%。
公告显示，公司H股于回购前后均保持在38,529,240股；A股则为190,203,760股，另有3,848,095股A股列作库藏股，合并后公司已发行股份总数仍为228,733,000股。公司于2025年6月10日获股东大会授予回购授权，授权回购上限为3,914,184股，此前已累积回购1,637,200股，占当日已发行股本的约4.1827%。
公司在公告中确认，回购事宜均符合相关上市规则及法律法规。公告由公司董秘兼联席公司秘书田敏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.